A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis - 07/09/13
, Masashi Iwabuchi, MD b, Naoto Inoue, MD c, Shigeru Nakamura, MD d, Ryuta Asano, MD e, Shinsuke Nanto, MD f, Yasuhiko Hayashi, MD g, Nobuo Shiode, MD g, Shigeru Saito, MD h, Yuji Ikari, MD i, Takeshi Kimura, MD j, Joji Hosokawa, MD k, Masato Nakamura, MD l, Jun-ichi Kotani, MD m, Ken Kozuma, MD n, Kazuaki Mitsudo, MD aRésumé |
Background |
The aim of this study was to investigate the efficacy and safety of paclitaxel-coated balloon (PCB) for the treatment of the bare-metal stent restenosis (BMS-ISR) and drug-eluting stent restenosis (DES-ISR).
Methods |
This study was a prospective, multicenter, randomized (2:1) trial conducted in 208 patients with 213 in-stent restenosis lesions (BMS-ISR: 123 lesions, DES-ISR: 90 lesions) at 13 centers in Japan. Patients were randomly assigned to a PCB group (137 patients with 142 lesions) or a conventional balloon angioplasty (BA) group (71 patients with 71 lesions). The primary end point was target vessel failure at 6-month follow-up.
Results |
Clinical and angiographic follow-up 6 months after intervention was performed in 207 patients (99.5%) with 208 lesions (97.7%). Target vessel failure was noted in 6.6% of the PCB group and 31.0% of the BA group (P < .001). Recurrent restenosis occurred in 4.3% of the PCB group and 31.9% of the BA group (P < .001). Late lumen loss was lower in the PCB group than in the BA group (0.11 ± 0.33 mm vs 0.49 ± 0.50 mm, P < .001). In PCB-treated lesions, recurrent restenosis occurred in 1.1% of patients with BMS-ISR and in 9.1% of patients with DES-ISR (P = .04). Late lumen loss was lower in patients with BMS-ISR than in patients with DES-ISR (0.05 ± 0.28 mm vs 0.18 ± 0.38 mm, P = .03).
Conclusions |
This randomized clinical study suggested that PCB provided much better clinical and angiographic outcomes than did conventional BA in patients with BMS-ISR and DES-ISR. Drug-eluting stent restenosis was associated with poorer outcomes compared with BMS-ISR after treatment with PCB.
Le texte complet de cet article est disponible en PDF.Plan
| Randomized controlled trial registration no. UMIN000008681. |
Vol 166 - N° 3
P. 527 - septembre 2013 Retour au numéro
Article précédent
- Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug-eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial
- Binita Shah, Vankeepuram S. Srinivas, Jiang Lu, Maria M. Brooks, Eric R. Bates, Zoran S. Nedeljkovic, Jorge Escobedo, Gladwin S. Das, John J. Lopez, Frederick Feit
- Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy
- Gjin Ndrepepa, Stefanie Schulz, Franz-Josef Neumann, Robert A. Byrne, Petra Hoppmann, Salvatore Cassese, Ilka Ott, Massimiliano Fusaro, Tareq Ibrahim, Tomohisa Tada, Gert Richardt, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?